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ABSTRACT
Despite recent advances in intensive chemotherapy treatments, long-term 
success is achieved in less than 30% of children with high-risk neuroblastoma (NB). 
Key regulatory pathways including the PI3K/Akt, mTOR and NF-κB are implicated in 
the pathogenesis of NB. Although drugs targeting these individual pathways are in 
clinical trials, they are not effective due to the activation of compensatory mechanisms. 
We have previously reported that natural novel withanolides from Physalis longifolia 
can potently inhibit these key regulatory pathways simultaneously. In the present 
study, we examined the efficacy and mechanisms through which novel withanolides 
and their acetate derivatives (WGA-TA and WGB-DA) from P.longifolia kill NB cells. 
The results from the study demonstrated that our novel acetate derivatives are highly 
effective in inhibiting the proliferation, shifting the cell cycle and inducing apoptosis 
in a dose dependent manner. Analysis of oncogenic pathway proteins targeted by 
withanolides indicated induction of heat shock response due to oxidative stress. Dose 
dependent decrease in clients of HSP90 chaperone function due to suppression of Akt, 
mTOR, and NF-κB pathways led to decrease in the expressions of target genes such as 
cyclin D1, N-myc and Survivin. Additionally, there was a dose dependent attenuation 
of the migration and invasion of NB cells. Furthermore, the lead compound WGA-TA 
showed significant reduction in tumor growth of NB xenografts. Taken together, these 
results suggest that withanolides are an effective therapeutic option against NBs.
INTRODUCTION
Neuroblastoma (NB) is an aggressive neural crest 
derived pediatric malignancy accounting for 8–10% of all 
pediatric cancers and is often refractory to conventional 
therapies [1, 2]. NB tumors exhibit clinical and molecular 
heterogeneity ranging from spontaneous regression in 
children less than 1 year to metastatic disease in older 
children complicating standardized treatment regimens. 
Although patients with low risk respond well to 
treatment, majority of the NB patients are detected with 
malignant metastatic spread and 40–50% of these high-
risk patients have N-myc oncogene amplification, which 
is one of the key prognostic factor of poor outcome in 
advanced stage NB. Despite intense multimodal therapy 
and improvements in understanding the molecular and 
genetic basis of NB, the therapeutic outcome of high risk 
children have a dismal long-term survival rate of only 
18–30% either due to recurrence after treatment or due 
to the development of resistance to conventional therapy 
[3]. Therefore, new treatment alternatives are needed to 
improve the poor outcome of advanced stage NB patients.
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Current treatment options for aggressive NB 
involves a coordinated sequence of multimodal 
treatment options such as induction chemotherapy, 
surgical resection of the primary tumor, high-dose 
myeloablative chemotherapy with autologous stem-cell 
transplantation (SCT), radiation, immunotherapy using 
anti-GD2 antibody and differentiation therapy using 13-
cis retinoic acid (CRA) for targeting the residual tumor 
[4]. In addition to the standard treatment options, targeted 
therapies using inhibitors of molecules implicated in 
the pathogenesis of NB such as anaplastic lymphoma 
kinase (ALK), tropomyosin receptor kinase (TRK), the 
phosphatidylinositol 3′-kinase (PI3K)/Akt/mammalian 
target of rapamycin (mTOR) and the insulin-like growth 
factor 1 receptor (IGF1R), histone deacetylases (HDAC) 
and others are in phase I/II clinical trials either alone or 
in combination [5–10] to improve the outcome of high-
risk NB patients. Despite advances in the development of 
targeted therapies and initial encouraging results, many 
patients later develop resistance to the targeted drug 
and relapse due to the activation of alternate pathways. 
Therefore, development of drugs targeting multiple 
pathways implicated in the pathogenesis of NB and has 
lower toxicity profiles are urgently needed.
Recently, natural compounds are gaining importance 
as anti-cancer therapeutics due to their non-toxic, anti-
carcinogenic activity and approximately 50% of FDA 
approved drugs are either natural products or their 
derivatives [11, 12]. As part of our investigation to 
develop anti-cancer drug leads from the plant diversity 
of the USA, our group has been developing natural and 
semi-synthetic withanolides that are 28-carbon steroidal 
lactones [13] found in Solanaceae family of plants as 
potential anti-cancer chemotherapeutic agents for several 
cancers including brain, head and neck, thyroid, breast, 
adrenal and other tumors [14–21]. Withanolides have 
thiol reactivity and have shown promising anti-tumor 
efficacy through modulation of many cellular pathways 
including the PI3K/Akt/mTOR, nuclear factor-κB (NF-
κB) and others [14, 18, 22–26] that are implicated in the 
pathogenesis of NB. They exert their anti-tumor efficacy 
through a mechanism of an oxidative stress response from 
metabolism of the epoxide in the B-ring and through their 
direct inhibition of HSP90/Cdc37 chaperone activity [27–
31]. In addition, withanolides have a large therapeutic 
index and selectivity for cancer cells. Hence, they are not 
plagued by the resistance mechanisms that effect mono-
targeted therapeutics. Therefore, they present novel potent 
anti-cancer therapeutics for children with NB. The main 
goal of the present study is to investigate the in vitro 
efficacy and mechanism of action of novel unmodified 
withaferin A (WA) and withalongolide A (WGA) as well 
as the semi-synthetic withanolides from the Physalis plant, 
namely withalongolide A 4, 19, 27-triacetate (WGA-TA) 
and Withalongolide B 4, 19 diacetate (WGB-DA) from 
Physalis longifolia that have shown potent anti-tumor 
efficacy in multiple cancer models during structure-
activity relationship analysis [28].
RESULTS
Withanolides are cytotoxic to NB cells
The proliferation of four different NB cell lines 
after 24 h or 72 h treatment with varying concentrations 
of withanolides (WA, WGA, WGA-TA or WGB-DA) was 
evaluated using MTS cell viability assay and the IC50 
values for each compound in NB cells were calculated 
using GraphPad Prism (Table 1A and 1B; Figure 1). Time 
dependent changes in IC50 was seen for all the cell lines 
tested as seen from changes in IC50 values from low µM 
at 24 h to low nM values. Of all the compounds tested 
higher efficacy for the acetate derivative compared to the 
parent compound were seen in all the NB cell lines tested 
both at 24 h and 72 h. The order of potency of withanolides 
tested were WGA-TA>WGB-DA>WA>WGA, indicating 
that the introduction of acetyl group significantly 
improves the potency of the parent compound. In addition 
fold selectivity for the most potent compound was 15–51 
fold higher in NB cells compared to normal fibroblast cells 
(data not shown). Two human NB cell lines (IMR 32 and 
GOTO) and the withanolides WA, WGA-TA, and WGB-
DA were used in all the subsequent mechanistic studies. 
Cell cycle distribution of NB cells is shifted after 
treatment with withanolides
As MTS assay absorbance measurement can be 
multifactorial, we assessed the distribution of cells in 
different phases of the cell cycle by flow cytometry after 
treatment with each withanolides for 24 h. Withanolide 
treatment of two NB cell lines IMR 32 and GOTO shifted 
the cells from G0/G1 phase to G2/M phase starting at 250 
nM in a dose-dependent manner with minimal changes 
in S-phase (Figure 2A–2D). Maximum shift to G2/M 
phase above the basal level was observed for both NB 
cell lines at 1 µM, 0.5–1 µM and 0.25–0.5 µM for WA, 
WGB-DA and WGA-TA respectively. In IMR 32 cells 
the percentage of cells in G2/M increases to 62.43%, 
46.07% and 40.47% after treatment with 1 µM WA, 1 µM 
WGB-DA and 0.5 µM WGA-TA respectively compared 
to 22.4% for the control untreated cells. Furthermore, in 
GOTO cells the percentage of G2/M increased to 56.9%, 
37.93% and 48.63% after treatment with 1 µM WA, 
0.5 µM WGB-DA and 0.5 µM WGA-TA respectively 
compared to 21.63% for the control untreated cells. In 
both cases, there were highly significant p values of 0.001. 
At higher drug concentrations (2–4 µM) where increase 
in apoptosis and cell debris was observed in the sub G0 
phase, the percentage of cells in G2/M levels decreased 
with increases in G0/G1 levels for both the NB cell lines.
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Withanolides induce apoptosis through caspase 
activation and PARP cleavage in NB cells
To explore whether the growth suppression 
mechanism of NB cells observed following exposure 
to withanolides (WA, WGA-TA or WGB-DA) is due 
to apoptotic or necrotic mechanism of cell death, 
annexin V-FITC/PI dual staining on flow cytometry was 
performed. The treatment of NB cell lines GOTO and IMR 
32 with increasing concentrations of each withanolide 
ranging from 0.5 µM–2 µM for 24 h resulted in increase 
in FITC-Annexin V / PI dual staining in a dose dependent 
manner. This result in both cell lines indicates enhanced 
apoptotic death with increasing drug dosage. From the 
basal levels of 3.6%, the number of dead cells (necrotic 
+ late and early apoptotic) increased in a dose dependent 
manner to 35.5%, 90.6% and 95.2% for WA, WGB-DA 
and WGA-TA respectively with significant p values of < 
0.001 at the highest concentration of 2 µM tested for IMR 
32 cells (Figure 3A and 3B), with increased necrotic cells 
seen at low concentrations for WGA-TA. In the case of 
GOTO cells also the percentage of dead cells increased 
in a dose dependent manner from a basal level of 2.66% 
to 44.49%, 74.28% and 89.09% for WA, WGB-DA and 
WGA-TA respectively at 2 µM (Figure 3D and 3E) with a 
p value of < 0.001 for the acetate derivatives and a p value 
of 0.01 for the parent compound. Induction of apoptosis 
was further confirmed by examining the cleavage and/
or total level of effector procaspases 3 and 7, and the 
downstream poly (ADP-ribose) polymerase (PARP) 
after treatment of both IMR 32 and GOTO with each 
withanolide for 24 h by western blot analysis. Treatment 
with increasing concentrations of withanolide resulted in 
progressively decreased levels of procaspases and poly 
ADP ribose polymerase (PARP) (Figure 3C and 3F). 
Cleavage of caspases 3 and 7, and PARP was observed 
starting at 1 µM for IMR 32 cells whereas for GOTO 
cells cleavage of caspases started at 2 µM although PARP 
cleavage occurred starting from 1 µM. Taken together the 
above results from the viability assay and flow cytometry 
analysis for cell cycle and apoptosis, indicated that the 
introduction of acetate derivative to the parent compound 
increases the potency of the drug.
Withanolides treatment of NB cells modulates 
Akt/mTOR/MAPK pathway proteins
To elucidate the mechanism through which 
withanolides induce apoptosis and suppress the viability of 
NB cells, we investigated the modulation of key regulatory 
Figure 1: Treatment of NB cells with novel withanolides has anti-proliferative effect. Cell viability was determined by MTS 
assay after treating NB cell lines IMR 32, GOTO, SH-EP1 and SK-N-As with varying concentrations of withanolides WA, WGB-DA or 
WGA-TA or solvent DMSO control for 72 h. Data presented are mean from triplicate value and error bars indicate standard error. The 
values are presented as percentage of control DMSO treatment.
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Table 1: Half-maximal inhibitory concentration (IC50) values for NB cells after withanolides 
treatment
A
24 h WA WGA WGB-DA WGA-TA
IMR32 2.09 ± 1.05 2.80 ± 0.72 1.19 ± 0.37 0.88 ± 0.23
GOTO 3.10 ± 1.57 4.30 ± 0.81 1.36 ± 0.47 0.89 ± 0.13
SH-EP1 3.42 ± 0.41 4.20 ± 0.91 1.16 ± 0.17 0.72 ± 0.23
SK-N-As 3.09 ± 1.16 2.98 ± 0.66 1.60 ± 0.19 0.52 ± 0.10
B
72 h WA WGA WGB-DA WGA-TA
IMR32 0.30 ± 0.02 0.50 ± 0.04 0.08 ± 0.03 0.02 ± 0.02
GOTO 0.58 ± 0.13 1.62 ± 0.03 0.27 ± 0.06 0.04 ± 0.08
SH-EP1 0.51 ± 0.05 0.68 ± 0.09 0.28 ± 0.01 0.19 ± 0.01
SK-N-As 0.23 ± 0.03 0.97 ± 0.09 0.14 ± 0.01 0.05 ± 0.01
The NB cells were treated with varying concentrations of WA, WGA, WGA-TA or WGB-DA for 24 h (A) and 72 h (B). MTS 
assay was used to determine viability and the values are presented as IC50 values in µM ± 95% CI.
Figure 2: Withanolides regulate the cell cycle effect of NB cells. The NB cells were stained with propidium iodide (PI) after 
treatment with varying concentrations of three different withanolides, WA, WGA-TA or WGB-DA, for 24 h and the cell cycle distribution 
was measured by flow cytometry (A–B) is IMR 32 cells and (C–D) is GOTO cells. The values of mean of three independent observations 
are presented.
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proteins involved in the proliferation of NB cells by 
western blot analysis. Since, N-myc plays a primary role 
in the pathogenesis and aggressiveness of NB and PI3K/
Akt pathway is known to stabilize N-myc protein, we 
first investigated the Akt/mTOR pathway proteins after 
treatment of both IMR 32 and GOTO cells with increasing 
concentrations (1–4 µM) of each withanolide (Figure 
4). At 24 h post treatment the levels of Akt decreased 
from 27% at 1 µM to complete inhibition by 4 µM for 
acetylated WGA-TA and from 8% (1 µM) to 85% (4 µM) 
for WA (non-acetylated, p < 0.01). Changes in the levels 
of mTOR, pmTOR and its downstream targets, p70-S6 
kinase and p-4EBP1, showed 9% inhibition at 1 µM for 
WA to complete knockdown at 1µM for WGA-TA in 
both NB cell lines. These results further confirmed the 
higher efficacy of the acetate derivatives and indicated 
that the withanolide treatment of NB cells suppressed 
the activation of Akt/mTOR pathway proteins as well 
the down-stream effectors of mTOR pathway involved in 
translation and protein synthesis. Since MAPK and Akt 
pathways are compensatory pathways we next assessed 
the expression levels of p-ERK and ERK (Figure 4). 
The results indicated no variation in the expression of 
total ERK, whereas the level of p-ERK increased with 
increasing concentration of withanolides indicating 
activation of the compensatory MAPK pathway.
Treatment with withanolides induces oxidative 
stress as well as heat shock response and 
pretreatment with thiol antioxident NAC blocks 
ROS and apoptosis of NB cells
Recent studies by our group and others have 
demonstrated that WA targets proteins involved in multiple 
cellular pathways through an oxidative response from the 
metabolism of the epoxide in the B-ring [18, 32, 33]. 
To determine whether withanolides induces oxidative 
stress in NB cells or not, we investigated induction of 
oxidative stress using CM-H2DCFDA staining method 
after treatment of NB cells with varying concentrations 
of WA and our novel acetate derivatives (WGB-DA and 
WGA-TA). Treatment of IMR 32 cells with 0.5–4 µM 
withanolides resulted in rapid and transient increase in 
mean DCF fluorescence peaking at 4 h that declined at 
7 h. The ROS production increased in a dose dependent 
manner to 4.06, 3.5 and 5.6 fold for WA, WGB-DA and 
Figure 3: Induction of apoptosis after novel withanolides treatment in NB cells. (A and D) IMR 32 and GOTO cells were 
stained with PI and annexin V-FITC and then analyzed by flow cytometry after treatment with increasing amounts of each withanolides. 
(B and E) Graphic representation of induction of apoptosis and necrosis after treatment of IMR 32 and GOTO cells with increasing 
concentrations of withanolides. Mean ± standard deviation results from three independent experiments are shown. (C and F) Western 
blot analysis of cleavage of PARP and caspases 3 and 7 after treatment of NB cells, IMR 32 and GOTO with novel withanolides for 24 h 
confirms induction of apoptosis. As a loading control actin was used.
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WGA-TA at the highest concentration of 4 µM tested with 
significant p values of 0.001, 0.002 and 0.005 respectively, 
compared to the control group (Figure 5A). When NB cells 
were treated with 5 mM NAC, which is a thiol antioxidant 
and ROS scavenger along with withanolides, generation 
of ROS was completely abrogated (Figure 5A and 5B) and 
returned to near basal levels with significant p-values of 
less than 0.001.
Withaferin A has been suggested to exert its anti-
cancer properties through direct inhibition of HSP90/
Cdc37 chaperone activity, induction of heat shock 
response and apoptosis following oxidative response 
in many cancer models [14, 18, 34]. In addition, heat 
shock protein HSP90 inhibition is known to induce 
HSP70. Furthermore, the HSP90/HSP70 chaperone 
machinery is known to induce degradation of HSP90 
client proteins through proteasome-dependent pathway 
[34, 35]. Since we observed degradation HSP90 client 
proteins and oxidative stress, we next determined whether 
withanolide treatment of NB cells induced heat shock 
response. Consistent with previous findings, withanolide 
treatment of NB cells also resulted in modulation of heat 
shock proteins, which was significantly reduced after 
treatment with NAC. Even though total levels of HSP90 
did not change the levels of HSP70 increased considerably 
starting at 1 µM withanolides for 24 h treatment, whereas 
levels of HSF 1 decreased in a dose dependent manner 
indicating inhibition of HSP90 (Figure 5C). The heat 
Figure 4: Treatment of IMR 32 (Left) and GOTO (Right) cells with withanolides modulate the proteins involved 
in Akt/mTOR/MAPK pathway. Following treatment of the NB cells with increasing concentrations of each withanolide for 24 h, 
expression levels of proteins from the Akt/mTOR/MAPK pathway was measured by immunoblot analysis using appropriate primary 
antibodies. Results indicate modulation of proteins with increasing concentrations of withanolides. Actin was used as a loading control.
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shock protein HSP32 expression increased with increasing 
concentrations of WA, whereas in the case of acetate 
derivatives the levels of HSP32 increased initially at 
low concentrations of 1 and 2 µM drug treatments and 
decreased at a higher concentration of 4 µM due to 
apoptosis (Figure 5C). Pretreatment of NB cells with NAC 
completely blocked the heat shock response, induction of 
apoptosis as well as down regulation of mTOR, p-mTOR, 
p70/85S6K, p-p70/85S6K and Iκ-Bα (Figure 5D and 5E)
Withanolides suppress activation of NF-κB, 
down regulate the expression of NF-κB target 
genes cyclinD1, survivin and N-myc as well as 
prevent migration and invasion of NB cells
Several studies have shown that withaolides 
including WA inhibits activation of NF-κB in tumor 
necrosis factor (TNF)-α stimulated cells by preventing 
the IκB phosphorylation and degradation [25, 36, 37]. 
Therefore, we next investigated whether NF-κB pathway 
is regulated by withanolides in NB cells. Evaluation 
of the NF-κB activity after 2 µM drug treatment by 
reporter assay indicated inhibition in activity for all the 
withanolides when IMR 32 cells were un induced, whereas 
the fold change in NF-κB activity in terms of untreated 
control decreased from 26.2 after TNF-α induction to 3.3, 
7.1 and 3.9 for WGA, WGB-DA and WGA-TA with a 
significant p value of 0.007, 0.01 and 0.006 respectively 
(Figure 6A). To determine the mechanism through which 
withanolides down regulate NF-κB activity, we performed 
immunoblot and immunofluorescence analysis. IMR 32 
cells treated with withanolides showed down regulation of 
Iκ-Bα in a dose-dependent manner starting at 2 µM. Even 
though total levels of p65 remained constant, treatment 
of withanolides inhibited the expression of phospho-p65 
(serine 536) starting at 1 µM drug treatment, preventing 
nuclear localization of NF-κB as shown in (Figure 6B, 
6D and 6E). Furthermore, withanolide treatment also 
Figure  5: Withanolides induce cellular stress response in NB cells. IMR 32 cells were preloaded with ROS indicator CM-
H2DCFDA prior to withanolides exposure and alteration in oxidation potential was measured. (A and B) Fluorescent intensity measurement 
revelaed the induction of ROS after 4 h of treatment in a dose dependent manner and complete blocking of this effect by 5 mM NAC co-
treatment. Immunoblot analysis of the stress response, heat shock proteins demonstrated increased expression levels of HSP32 and HSP70, 
and decreased expression of HSF1 after 24 h of treatment with increasing concentrations of withanolides. When the cells were pre-treated 
with NAC, cleavage of PARP that is an indicator of apoptosis was blocked and the increase in the expression levels of the heat shock 
proteins HSP32 and HSP70 as well as decrease in expression levels of mTOR pathway proteins and Iκ-Bα are blocked after NAC treatment, 
indicating attenuation of the anti-proliferative properties of withanolides by NAC (C–E).
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inhibited NF-κB downstream genes such as cyclin D1, 
survivin and N-myc (Figure 6C). Pretreatment of cells 
with thiol antioxidant NAC, blocked the inhibition of 
NF-κB with significant p values of 0.002, 0.001 and 0.01 
for WA, WGB-DA and WGA-TA respectively, indicating 
thiol oxidation and Hsp90 mediated inhibition of NF-κB 
by withanolides (data not shown). As NF-kB is known to 
mediate invasion and metastasis, we performed wound 
assay as well as Boyden chamber invasion experiment 
after treatment of IMR 32 cells with withanolides. As 
expected, we observed migration of cells in the wound 
area for the control cells which was prevented by 
treatment of IMR 32 cells with 2 µM of either WGA or 
WGB-DA or WGA-TA. Analysis of migration of cells 
through a matrigel further confirmed the observation as 
treatment of IMR 32 cells with the acetate derivatives 
WGB-DA and WGA-TA attenuated the migration of more 
than 80% cells with significant p value of 0.01, whereas 
only 4 µM WGA had blocked the migration and not 2 µM 
WGA (Figure 6F, 6G and 6H). Overall, the results of the 
Figure 6: Down regulation of the NF-κB activity after withanolide treatment leads to down regulation of p-p65 
(ser536), targets N-myc and prevents migration as well as invasion of NB cells. (A) NB cell line IMR 32 was transfected with 
0.5 mg of NF-kB reporter along with 50 ng of renilla luciferase by lipofectamine 2000. 24 h post transfection, the cells either were treated 
with 2 μM withanolides (WA, WGB-DA or WGA-TA) for 3 h before treatment with TNF-α for 16 h for TNF-α mediated NF-κB activity 
and left untreated for uninduced NF-κB activity. The luciferase activity was measured 24 h post addition of withanolides using Promega 
dual luciferase assay kit. (B) Western blot analysis of p-p65 (ser536) and Iκ-Bα demonstrating degradation of Iκ-Bα and down regulation 
of phospho-p65 (ser 536) whereas total levels of p65 remains unchanged. (C) Down regulation of NF-κB target genes such as N-myc, 
cyclin D1 and survivin in a dose dependent manner after 24 h treatment of IMR 32 cells with withanolides. (D and E). Imuuno fluorescence 
analysis of p65 after withanolides treatment evaluated by confocal microscopy indicated cytosolic presence of p65. Absence of nuclear 
staining of p65 showed inhibition of NF-κB due to prevention of nuclear localization of p65. DAPI was used for staining nuclei. This was 
further confirmed by the cytosolic and nuclear fractionation immunoblots. The same blot was stripped and reprobed for tubulin and lamin 
A/C after immunoblotting for p65 to verify the integrity of the cytosolic and nuclear fractions. (F–H). The acetate derivatives effectively 
block migration and invasion of IMR 32 cells as seen in wound healing and Boyden chamber invasion assays.
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study clearly demonstrate the improved efficacy of the 
acetate derivatives of withanolides compared to parent 
compound in modulating key pathways implicated in the 
pathogenesis of NB and inducing cell death.
Treatment with WGA-TA causes tumor 
regression
To evaluate the in vivo efficacy of the lead 
compound WGA-TA, in the present study we used human 
neuroblastoma cell line IMR32 xenografts. Treatment of 
mice with WGA-TA for 3 weeks resulted in statistically 
significant decrease in tumor burden starting from day 
15 and continued till the end of the study (Figure 7A and 
7B). The study was stopped as all the control mice reached 
the maximum tumor volume approved by our UCUCA 
protocol. At the end of the study period the withanolide 
WGA-TA treatment groups showed 68.9% decrease in 
tumor volume compared to the control groups. In addition, 
the average tumor weights of the WGA-TA treatment 
groups decreased to 0.67 gram compared to the control 
group value of 2.04 gram with a significant p value of 0.01 
(Figure 7C and 7D).
DISCUSSION
NB is an embryonic solid tumor with poor 
therapeutic outcome for children with high risk tumors. 
Recent studies have detected activated expression of pAkt 
and pmTOR in primary neuroblastoma tumors and in 
differentiated ganglion cells. Additionally, activation of 
Akt is shown to be associated with poor prognosis in NB 
[38]. Furthermore, increased expression of several growth 
factors such as tyrosine receptor kinase B (TrkB), insulin 
–like growth factor (IGF-1R) and epidermal growth factor 
(EGFR) that transmit their signals through PI3/Akt/mTOR 
pathway are known to be associated with drug resistance 
and increased expression of N-myc in NB [39]. Therefore, 
targeted therapies using PI3K/Akt/mTOR inhibitors, 
anti-angiogenic drugs and ALK antagonists are in phase 
I/II clinical trials either alone or in combination with 
conventional chemotherapy for refractory or recurrent NB 
[6]. The problem that will plague these and other single-
target drugs is the cancer’s ability to activate alternative 
survival pathways leading to drug resistance and toxicity 
even in the multi-modality setting. Therefore, novel multi 
targeted treatment options with fewer adverse effects and 
toxicity are needed for NB.
Our group over the last few years has demonstrated 
the anti-cancer properties of novel withanolides from 
P.Longifolia in various cancer models both in vitro and in 
vivo. Not only are these natural products extremely safe in 
vivo, but they also function through a unique mechanism of 
action leading to the simultaneous and selective inhibition 
of key regulatory pathways including Notch/PI3K/Akt/
mTOR/NF-κB in cancers [18, 22, 26, 30]. These natural 
compounds utilize a multi-targeted approach through 
their unique mechanism of action: inducing an oxidative 
Figure 7: Treatment of IMR32 xenografts with WGA-TA leads to tumor regression. (A and B) Tumor growth curve and 
explanted tumors. (C and D) Average tumor volume and tumor weight at the end of the study period of 24 days.
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stress response (via generation of reactive oxygen species 
following metabolism of the epoxide on the B-ring of the 
molecule) in cancer cells coupled with a novel means of 
inhibiting HSP90 chaperone function through blockade of 
Cdc37 docking. This in turn prevents kinase activation by 
HSP90 leading to targeting of key tumorigenic proteins 
that are implicated in invasion and poor survival of NB. 
Hence, the present study was designed to investigate the 
mechanism through which novel natural and semisynthetic 
withanolides from P.longifolia target and induce cell 
death in NB. The results from the viability assay clearly 
demonstrated that our novel withanolides are effective in 
targeting both N-myc amplified and non-amplified cell 
lines at nano molar IC50 concentrations. In addition, the 
acetate derivatives WGA-TA and WGB-DA were able to 
induce potent dose dependent apoptosis and G2/M cell 
cycle arrest at low concentration of 500 nM compared 
to 2 µM for withaferin A indicating that they are highly 
potent in targeting the NB cells compared to the parent 
withanolide. 
Deregulated PI3K/Akt/mTOR pathway proteins 
and tyrosine kinases are implicated in the development 
and poor survival of NB. Therefore, to determine how 
withanolides would modulate these key pathway proteins, 
we examined their levels of expression by western blot 
analysis. We observed inhibition of many key survival 
proteins involved in this pathway like Akt, pAkt, mTOR, 
p-mTOR and their downstream effectors such as pS6K 
and p4E-BP1 in both the NB cell lines tested. Further, 
to elucidate whether withanolides would target MAPK 
proteins we examined activation of ERK in NB cells. Even 
though activation of ERK is considered a survival signal, 
its activation is also associated with oxidative stress 
induced cell death [40, 41]. Our results revealed prolonged 
activation of ERK that is associated with proapoptotic 
properties of ERK until the duration of the experiment (24 
h) in NB cell lines, suggesting the possible role of ERK 
in mediating pro apoptotic signaling after withanolides 
treatment in NB cells. The observed cleavage of apoptotic 
markers such as caspase 3 and PARP further confirmed 
withanolide mediated induction of apoptosis in NB cells. 
Overall these results, along with the previous studies by 
Yco et al. [42] that showed inhibition of signal transducer 
and activator of transcription 3 (STAT3) by WA, indicate 
that withanolides have the ability to target both the 
upstream and downstream components of the PI3K/Akt/
mTOR/MAPK pathway proteins that are implicated in the 
poor prognosis of NB. This results in maximal inhibition 
and/or avoidance of negative feedback loops that are 
responsible for the development of drug resistance. In 
addition, targeting multiple nodes of this critical pathway 
may offer the added benefit of restoring sensitivity to the 
anti-cancer drugs to which the NB patients have become 
resistance. Future studies using drug resistant NB cell 
lines are needed to explore whether our novel withanolides 
can sensitize the drug resistant NB tumors.
Induction of reactive oxygen species and alteration 
in redox potential of cancer cells after treatment with 
chemotherapeutics has been observed in many cancer 
models as malignant cells are much more susceptible to 
oxidative stress-induced cell death compared to normal 
cells [43, 44]. Even though the mechanism through which 
WA induces ROS is not well defined, studies have shown 
induction of oxidative stress after WA treatment in breast 
cancer and glioblastoma [18, 30]. In NB cells we also 
observed induction of oxidative stress following treatment 
with withanoldies in a dose dependent manner. Following 
oxidative stress, heat shock proteins HSP32 and HSP70 
were upregulated, while the levels of HSP90 remained the 
same. WA is known to directly bind to HSP90 and inhibit 
HSP90 through an ATP independent mechanism leading 
to degradation of client proteins [27]. Induction of HSP70 
and degradation of many client proteins of HSP90 such as 
Akt, mTOR, N-myc, cyclinD1 clearly indicates inhibition 
of HSP90 with withanolide treatment in NB cells. To 
further confirm withanolides bind to HSP90 reactive 
cysteine, NB cells were pretreated with NAC. Regardless 
of the mechanism through which NAC pretreatment of 
NB cells reverses the withanolide effect (either through 
chemical reaction or through oxidative response), our 
results revealed inhibition of HSP90, prevention of 
upregulation of heat shock proteins and attenuation of cell 
death. 
As withanolide treatment of NB cells demonstrated 
down regulation of Akt, induction of oxidative stress 
and inhibition of HSP90 function all of which are key 
regulators of NF-κB, we examined the modulation of 
NF-κB using reporter assay. Our results demonstrated 
attenuation of NF-κB in a dose dependent manner due 
to prevention of nuclear localization of NF-κB as seen 
by our immunocytochemistry results. Although several 
withanolides have shown inhibition of NF-κB activation, 
the exact mechanism through which withanolides inhibit 
NF-κB is not clearly defined. Previous studies have shown 
two contributing factors for the suppression of NF-κB. 
The first is the prevention of Iκ-Bα phosphorylation and 
degradation with subsequent reduction of nuclear NF-
κB and the second mechanism is through targeting IKKs 
due to HSP90 inhibition. Results from our immunoblot 
analysis revealed degradataion of Iκ-Bα and a decrease in 
the phosphorylation of p65 at ser536 in a dose-dependent 
manner without altering the total levels of p65. Studies by 
Paimela et al. have shown modulation of NF-κB activity 
and down regulation of p65 at serine 536 via HSP70 
regulation after celastrol treatment of retinal pigment 
epithelial cells [45]. Since we observed up regulation of 
HSP70 due to induction of oxidative stress and inhibition 
of HSP90 activity, one possible mechanism through 
which withanolides inhibit NF-kB activation in NB cells 
may be via suppression of nuclear translocation of NF-κB 
through attenuation of serine 536 phosphorylation of p65. 
Further analysis of the target genes of NF-κB revealed 
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down regulation of cell cycle regulator cyclinD1, survivin 
and N-myc. Given that in majority of high-risk NBs cell 
cycle exit and terminal differentiation that occurs during 
neuroblast development are disrupted by high N-myc 
expression. Additionally, Akt phosphorylation is known 
to be correlated with N-myc and PI3K/Akt signaling 
is known to prevent degradation of N-myc. Hence, 
suppression of N-myc, which is a key prognostic factor 
in high-risk NB, is targeted by withanolides through 
modulation of multiple factors such as Akt, mTOR, GSK-
3β, NF-κB etc. Many of the genes that are involved in 
the migration and metastasis of cancer cells like vascular 
endothelial growth factor and matric metallo proteinases 
are regulated by NF-κB. Therefore, we evaluated whether 
suppression of NF-κB by withanolides can prevent 
migration of NB cells using wound healing assay and 
matrigel invasion assay. Our results clearly demonstrated 
that our novel withanoldies prevents migration and 
invasion of NB cells through down regulating NF-κB.
In summary, this study for the first time reveals the 
detailed mechanism through which natural withanolide, 
WGA isolated from P.longifolia, and its semi synthetic 
acetate derivatives (WGB-DA and WGA-TA) induce cell 
death in NB cells. Based on the results from our study, one 
possible mechanism through which withanolides prevent 
migration and potentiate apoptosis and cell cycle arrest in 
NB cells is through induction of oxidative stress coupled 
with a novel mechanism of HSP90 inhibition, which in NB 
targets key tumorigenic proteins such as Akt, mTOR, NF-
κB and N-myc. Down regulation of these oncogenic signal 
transduction pathway proteins in turn leads to suppression 
of migration and invasion of NB cells. Convincing 
evidence from our in vitro results and given that naturally 
derived withanolides unlike chemotherapeutics are 
less toxic, support further translational development of 
withanolides as a novel anticancer drug for NB patients. 
However, future in vivo efficacy and toxicity studies in NB 
xenografts are warranted to validate the clinical application 
of our novel withanolides as potential therapeutics for NB.
MATERIALS AND METHODS
Cell culture and reagents
Validated human NB cell lines IMR 32, SH-EP1, 
SK-N-As and GOTO were grown in Minimum Essential 
Medium (MEM; Life Technologies, Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS; Sigma-
Aldrich, St. Louis, MO) and 1% penicillin/streptomycin 
(Life Technologies, Grand Island, NY). IMR 32 medium 
is additionally supplemented with 1% MEM non-essential 
amino acids (100X; Sigma-Aldrich), 2 mM of L-glutamine 
(200 mM; Sigma-Aldrich), 1 mM sodium pyruvate 
(100mM; Sigma-Aldrich), and 1500 mg/L of sodium 
bicarbonate (7.5%; Sigma-Aldrich). All the cell lines 
were incubated in a humidified atmosphere of 5% CO2 in 
air at 37oC. The structure of the withanolides used in the 
study namely WA, WGA, WGA-TA and WGB-DA were 
previously described [15] and were obtained from Dr. 
Barbara Timmermann’s laboratory (Lawrence, Kansas). 
Reagents used in the flow cytometry analysis for cell cycle 
and apoptosis such as propidium idodide (PI), RNase 
were obtained from Sigma-Aldrich ((St. Louis, MO) and 
Annexin V-FITC was obtained from BD biosciences (San 
Diego, CA). N-acetyl-L-cysteine (NAC) was obtained 
from Sigma-Aldrich (St. Louis, MO) and CM-H2DCFDA 
was from Molecular Probes (Grand Island, NY).
Evaluation of cytotoxicity
To measure the drug efficacy of withanolides on 
NB cell lines IMR 32, SH-EP1, SK-N-As, and GOTO 
cells were seeded in a 96 well plates at a density of 
3000 cells per well and the viability was determined 
by the colorimetric CellTiter96 Aqueous MTS assay as 
per the manufacturer’s protocol (Promega, Fitchburg, 
WI). The cells were treated with serial dilutions ranging 
from 0.0195–10 µM of WA, WGA-TA or WGB-DA 
and incubated for either 24 h or 72 h at 37oC in a CO2 
humidified chamber. At the end of the treatment period, 
absorbance at 490 nm was recorded on a BioTek Synergy 
2 plate reader (BioTek, Winooski, VT) after the addition 
of MTS reagent and cytotoxicity was expressed as a 
percentage of control untreated cells. For NAC co-
treatment with withanolides, CellTiter-Glo luminescent 
assay (Promega, Fitchburg, WI) was used to determine 
the viability to avoid the auto-reductive potential of NAC 
that interferes with MTS. The viability was determined by 
measuring the adenosine triphosphate levels (ATP) as per 
the manufacturer’s protocol. Experiments were performed 
in triplicate and the values were expressed as means ± S.D. 
The half-maximal inhibitory concentrations (IC50) and p 
values were calculated using Graphpad Prism and excel. 
Flow cytometry for the analysis of cell cycle and 
apoptosis
The NB cell lines IMR 32 and GOTO grown to 60–
80% confluence in 60 mm plates were treated with 0.25–2 
µM of WA, WGA-TA or WGB-DA for 24 h. The cells 
were then harvested, resuspended in 0.43 mL of ice cold 
1X phosphate buffered saline (PBS) followed by 1 mL 
of ice cold ethanol to get a 70% ethanol fixative solution 
and stored at –20oC until analysis. Finally, the cells were 
pelleted by centrifugation, stained with propidium iodide 
(PI) solution (40 μg/mL PI and 100 mg/mL RNaseA), and 
incubated at 37oC for 30 minutes before cell cycle analysis 
using CyAn™ ADP Analyzer (Beckman Coulter, Inc., 
Brea, CA) at the University of Michigan Flow Cytometry 
Core. Each experiment was repeated thrice and only viable 
cells without DNA fragmentation were analyzed using 
FlowJo software (Tree Star, Inc., Ashland, OR). 
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Phosphatidylserine staining with annexin on the 
outer leaflet of the cell membranes for apoptotic cells, 
and DNA staining by PI for necrotic and late apoptotic 
cells was performed for the analysis of cell death. IMR 
32 and GOTO cells grown and treated with varying 
concentrations of WA or WGA-TA or WGB-DA for 24 
h as in cell cycle analysis were trypsinized, collected 
and washed once with Annexin binding buffer [18]. The 
cells were then stained using Annexin V- fluorescein 
isothiocyanate (FITC)/PI staining according to the 
manufacturer’s protocol (BD Biosciences, San Diego, 
CA) and induction of apoptosis was measured using the 
CyAn™ ADP Analyzer. Experiments were repeated thrice 
to confirm the results.
Immunoblot analysis
The NB cell lines IMR 32 and GOTO grown to 
50% confluence was treated with varying concentrations 
of withanolide derivatives WA, WGA-TA or WGB-DA for 
24 h. For NAC treatment the IMR 32 cells were pretreated 
for 1 h with 5 mM NAC before drug treatment. The 
cells were then collected in lysis buffer and the proteins 
were quantified using the BCA Protein Assay (Thermo 
Scientific, Rockford, IL) as previously described [32]. 
Equal amounts of proteins were separated using SDS-
PAGE and then transferred onto a Hybond nitrocellulose 
membrane (GE Healthcare Life Sciences, Piscataway, NJ). 
The membranes were blocked and probed with appropriate 
dilutions of the primary and secondary antibodies then 
visualized using Super signal Chemiluminescence Reagent 
(Thermo Scientific, Rockford, IL) as previously described 
[18]. Actin control was used to ensure equal loading 
of proteins and for transfer efficiency. Densitometric 
analysis was performed using Image J software (NIH). 
The cytosolic and nuclear fractions were prepared after 
treatment of IMR32 cells with withanolides using NE-PER 
nuclear and cytoplasmic extraction kit (Thermo Scientific, 
Rockford, IL) as per the manufacturer’s protocol. The 
integrity of the cytosolic and nuclear fractions were 
verified by immunoblotting for tubulin and lamin A/C.
Measurement of reactive oxygen species (ROS)
A general oxidative stress indicator CM-H2DCFDA 
that fluoresces upon oxidation was used to determine 
the accumulation of intracellular peroxide type reactive 
oxygen species. IMR 32 cells were incubated at 37oC with 
20 µM CM-H2DCFDA in 1X PBS for 1 h for preloading 
of the probe and then plated in 96 well plates at a density 
of 20,000 cells per well in phenol red free medium. After 
30 min, varying concentrations of withanolides (1–5 µM) 
and/or 5 mM NAC was added and the fluorescence was 
assessed 3–5 h post treatment using BioTek Synergy plate 
reader with excitation and emission filters of 485 nm and 
528 nm respectively.
Immunocytochemistry
Approximately 25,000 IMR 32 cells were seeded in 
an eight well chamber slides (Nalgene Nunc International, 
Penfield, NY) and were allowed to attach overnight. The 
cells were treated with 2 µM of WA, WGA-TA or WGB-
DA for 24 h and then fixed using 4% paraformaldehyde 
for 30 min. The cells were washed three times with 1X 
phosphate buffered saline (PBS), permeabilized using 
0.3% triton X-100 for 15 min. after which they were 
blocked with 5% normal goat serum (Cell Signaling 
Technology) for 1 h at room temperature. The primary 
antibody for p65 (cell Signaling Technology) at a dilution 
of 1:500 in 1X PBS was added to the cells and the cells 
were incubated at 4oC overnight. After incubation with 
primary antibody, the cells were washed with 1X PBS 
three times and then incubated with secondary antibody 
(1:1000; anti-rabbit IgG Fab2 Alexa Fluor 555, Cell 
Signaling #4413) for 1 h at room temperature. Finally the 
cells were washed thrice with 1X PBS, mounted on a slide 
with ProLong Gold Antifade with DAPI (Cell Signaling 
Technology) and imaged using NIS Elements software and 
Nikon A1Rsi Confocal Microscope.
NF-κB reporter assay
The NB cell line IMR 32 grown to 60–70% 
confluence was transfected with NF-κB reporter plasmid 
pBVIx-Luc [46] along with Renilla luciferase plasmid (a 
gift from Dr. Eric R. Fearon, University of Michigan) by 
lipofectamine 2000 as per the manufacturer’s protocol. 24 
h post transfection, the cells were treated with either with 
2 µM WA, WGA-TA or WGB-DA for 3 h before treatment 
with TNF-α for another 16 h. NF-κB activity was then 
measured using Dual-Luciferase Reporter (DLR) assay kit 
from Promega as per the manufacturer’s instruction. For 
NAC treatment the cells were pretreated with 5 mM NAC 
1 h before drug treatment.
Scratch wound healing assay
IMR 32 cells grown to 70–80% confluence as a 
monolayer were scratched using a pipette tip to create 
a wound. The unattached cells were washed with fresh 
medium and then the cells were treated with 2 µM of each 
withanolides. The cells were washed with 1X PBS and 
then photographed using a phase contrast microscope at 
time 0 h (immediately after the scratch) and 24 h after 
scratch to monitor the migration of cells into the wounded 
area [47]. 
Matrigel invasion assay
Assays were done in triplicate in inversion 
chambers pre-coated with Matrigel (BD Biosciences) 
to assess the invasive properties of the cells. The inserts 
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were transferred in to the 24-well plate containing 0.75 
mL culture medium with 10% FBS and approximately 
50,000 IMR 32 cells in 0.5 mL of serum free medium 
were seeded on to the atypical side of the insert. The 
plates were incubated at 37oC, 5% CO2 atmosphere for 24 
h after treatment with 2 µM withanolides (WA, WGA-TA 
or WGB-DA). At the end of the treatment the non-invaded 
cells were removed using a cotton swab and the invaded 
cells at the lower side of the insert membrane was stained 
with crystal violet, air dried and imaged. For calorimetric 
estimation of the invaded cells, the inserts were treated 
with 150 µL of 10% acetic acid and the absorbance was 
measured at 560 nm using a BioTek plate reader.
IMR32 xenografts
Athymic nude mice were injected with 
approximately 3million IMR32 human neuroblastoma 
cell lines subcutaneously in the right flank. Once the 
tumors reached the size of 4mm2 diameter the mice were 
randomized into control and WGA-TA treatment groups. 
Control groups received solvent where as the treatment 
groups received 6mg/kg WGA-TA in 50mg/ml captisol. 
Tumor size and volume were measured thrice weekly and 
the mice were sacrificed once the tumor volume reached 
greater than 2000 mm3. All procedures were performed in 
accordance with the University of Michigan Animal care 
and use committee (UCUCA) approved protocol.
Statistical analysis
The IC50 curves were generated using best fit 
nonlinear sigmoidal dose response curves in GraphPad 
Prism 6. Differences between mean values were 
determined by Student’s unpaired t-test using Excel 
or GraphPad Prism. Each experiment was repeated at 
least three times and data are presented as mean values 
with standard deviation/ standard error as error bars. 
P-values less than 0.05 were set as significance for all the 
calculations.
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